Skip to content
drillr.ai
Sign up

GERN

Geron Corporation

NASDAQ · Healthcare · Biotechnology · US

$1.57
+3.97%
Ask drillr

  • Aug 5, 2026, 11:00 UTC

    Geron Corporation reported second quarter 2026 financial results, with RYTELO net product revenue of $57.5 million, an 11% increase from the first quarter of 2026, and cash and marketable securities of $327 million at the end of the quarter.

    Source:

  • Jul 13, 2026, 12:00 UTC

    Geron Corporation appointed Chinmaya Rath as Chief Business Officer.

    Source:

  • Jul 1, 2026, 14:11 UTC

    Geron Corporation reported Q1'26 Rytelo revenues of $51.8 million, up 8% sequentially, with two consecutive quarters of demand growth.

    Source:

  • Jun 1, 2026, 20:05 UTC

    Fulcrum Therapeutics discontinued its pociredir program in sickle cell disease following FDA feedback about secondary malignancies observed with Tazverik and its global withdrawal.

    Source:

  • Jun 1, 2026, 18:06 UTC

    Replimune aligned with the FDA on plans to resubmit its Biologics License Application for RP1 plus Opdivo in advanced melanoma.

    Source:

  • Jun 1, 2026, 18:00 UTC

    Merck's calderasib plus Keytruda received FDA Breakthrough Therapy designation for newly diagnosed metastatic KRAS G12C-mutant NSCLC patients.

    Source:

  • Jun 1, 2026, 16:32 UTC

    Iovance Biotherapeutics obtained FDA clearance of an Investigational New Drug application for IOV-5001, extending its cell therapy platform into solid tumors.

    Source:

  • Jun 1, 2026, 12:30 UTC

    PolyPid completed a New Drug Application submission to the FDA for D-PLEX100.

    Source:

  • Jun 1, 2026, 11:00 UTC

    Kamada Ltd. received FDA approval for its new in-house Rabies Virus Neutralization Testing Laboratory.

    Source:

  • Jun 1, 2026, 09:53 UTC

    Geron received FDA approval for RYTELO in low- to intermediate-1 risk MDS.

    Source: